CA-FORESCOUT
24.5.2022 14:02:05 CEST | Business Wire | Press release
Forescout Technologies , the leader in automated cybersecurity, today announced the launch of Forescout Frontline , a new threat hunting service utilizing a team of highly-trained cybersecurity analysts to support cybersecurity teams by proactively identifying risks, enabling accelerated incident response, and maturing security posture. Forescout is offering this complimentary service for organizations that lack the internal resources and visibility to defend themselves from cybersecurity attacks, including ransomware and advanced persistent threats (APT).
“Cybersecurity attacks are on the rise. Simultaneously, cybersecurity teams are perennially understaffed and under resourced. This has created a perfect storm,” said Shawn Taylor, vice president of threat defense. “Organizations are under immense pressure to cope with the scale and speed of attacks and the havoc caused by the adversaries. Forescout is launching this new service to help organizations defend against attacks by providing a complete and holistic view of their assets.”
Many organizations use multiple security tools across multiple teams to help identify threats and risks. However, insights may be limited due to siloed views of IT, IoT, IoMT or OT assets. Typically, a variety of these asset types exist across an organization’s digital terrain and are often interconnected, which means cybersecurity risk must be identified and tackled holistically.
Delivered by Forescout Frontline analysts, the Threat Hunting and Risk Identification Service overcomes staffing resources and asset visibility challenges to uncover threats and identify risks that may otherwise remain undiscovered. Forescout Frontline will help organizations:
- Discover, validate and prioritize a wide variety of cyber threats and vulnerabilities across all assets, including IT, IoT, IoMT and OT
- Analyze the context and risk associated with all findings
- Leverage the comprehensive insights to develop effective risk mitigation and remediation strategies
A State of Florida Agency, which supports several key Florida departments, engaged Forescout Frontline to understand each instance of Log4j, a zero-day vulnerability in a popular Java logging framework, across the organization’s 220 sites in 16 diverse divisions. In less than a day and a half, Forescout Frontline delivered insights into thousands of assets with vulnerabilities such as Log4j and Windows-based PrintNightmare. Additionally, hundreds of Critical CVSS-rated vulnerabilities affecting infrastructure devices such as switches and routers were found. Finally, actionable intelligence concerning critical embedded IoT TCP-IP stack-based instances such as NUCLEUS: 13 and RIPPLE 20, insecure communications, and other risks were also discovered. Leveraging this free service shrunk time to mitigation and remediation of these security gaps and improved overall security posture.
“When Log4J broke, we knew it was a critical issue, but we lacked a full picture of the risk within our extended enterprise. The [Forescout threat hunting] report was way more thorough than I expected, with in-depth information and actionable intelligence. Not just on Log4j but on other critical vulnerabilities as well, and not just in general terms but exactly where they exist in our environment.” – Information Security Manager, State of Florida Agency
Forescout Frontline levels the cybersecurity playing field by operationalizing the vulnerability research and threat intelligence produced by Forescout’s Vedere Labs and enhancing it with the Forescout Continuum Platform to provide threat hunting services across multiple dimensions. Forescout Frontline analysts include former public sector and private sector threat hunters with training in threat detection and incident response.
To learn more about Forescout Frontline, visit here , and for further insight into how a State of Florida agency benefitted from this new service, visit here.
About Forescout
Forescout Technologies, Inc. delivers automated cybersecurity across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types – IT, OT, IoT, IoMT. The Forescout Continuum Platform provides complete asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets.
Managing cyber risk, together.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005112/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
